

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-36715

**Nevro Corp.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

56-2568057

(I.R.S. Employer Identification No.)

1800 Bridge Parkway  
Redwood City, CA

(Address of principal executive offices)

94065

(Zip Code)

(650) 251-0005

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Common Stock, \$0.001 par value per share

Trading Symbol

NVRO

Name of each exchange on which registered

The New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 6, 2024, there were 37,471,622 shares of the registrant's common stock, par value \$0.001 per share, outstanding.

**Nevro Corp.**  
**TABLE OF CONTENTS**

	Page
<b><u>PART I—FINANCIAL INFORMATION</u></b>	3
<u><a href="#">Item 1. Condensed Consolidated Financial Statements (unaudited)</a></u>	3
<u><a href="#">Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</a></u>	3
<u><a href="#">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023</a></u>	4
<u><a href="#">Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2024 and 2023</a></u>	5
<u><a href="#">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023</a></u>	6
<u><a href="#">Notes to Condensed Consolidated Financial Statements</a></u>	7
<u><a href="#">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></u>	20
<u><a href="#">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></u>	32
<u><a href="#">Item 4. Controls and Procedures</a></u>	32
<b><u>PART II—OTHER INFORMATION</u></b>	33
<u><a href="#">Item 1. Legal Proceedings</a></u>	33
<u><a href="#">Item 1A. Risk Factors</a></u>	33
<u><a href="#">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></u>	33
<u><a href="#">Item 3. Defaults Upon Senior Securities</a></u>	33
<u><a href="#">Item 4. Mine Safety Disclosures</a></u>	33
<u><a href="#">Item 5. Other Information</a></u>	33
<u><a href="#">Item 6. Exhibits</a></u>	34
<b><u>SIGNATURES</u></b>	36

**PART I—FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements**

**Nevro Corp.**  
**Condensed Consolidated Balance Sheets**  
**(unaudited)**  
**(in thousands, except share and per share data)**

	September 30, 2024	December 31, 2023
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 71,982	\$ 104,217
Short-term investments	205,056	218,506
Accounts receivable, net of allowance for doubtful accounts of \$1,292 and \$1,048 at September 30, 2024 and December 31, 2023, respectively	70,601	79,377
Inventories	120,412	118,676
Prepaid expenses and other current assets	11,189	10,145
Total current assets	479,240	530,921
Property and equipment, net	24,928	24,568
Operating lease assets	21,776	8,944
Goodwill	38,209	38,164
Intangible assets, net	25,144	27,354
Other assets	5,745	5,156
Restricted cash	606	606
Total assets	<u>\$ 595,648</u>	<u>\$ 635,713</u>
<b>Liabilities and stockholders' equity</b>		
Current liabilities		
Accounts payable	\$ 20,309	\$ 22,520
Accrued liabilities	34,943	45,297
Short-term debt	37,906	—
Contingent liabilities, current portion	1,912	9,836
Other current liabilities	343	5,722
Total current liabilities	95,413	83,375
Long-term debt	184,364	211,471
Long-term operating lease liabilities	24,321	4,634
Contingent liabilities, non-current portion	13,501	12,257
Warrant liability	2,238	28,739
Other long-term liabilities	2,168	2,092
Total liabilities	322,005	342,568
Commitments and contingencies (Note 6)		
Stockholders' equity		
Preferred stock, \$0.001 par value, 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; zero shares issued and outstanding at September 30, 2024 and December 31, 2023	—	—
Common stock, \$0.001 par value, 290,000,000 shares authorized at September 30, 2024 and December 31, 2023; 38,111,415 and 37,044,390 shares issued at September 30, 2024 and December 31, 2023, respectively; 37,439,555 and 36,361,474 shares outstanding at September 30, 2024 and December 31, 2023, respectively	37	36
Additional paid-in capital	1,031,899	992,762
Accumulated other comprehensive income (loss)	1,445	(243)
Accumulated deficit	(759,738)	(699,410)
Total stockholders' equity	273,643	293,145
Total liabilities and stockholders' equity	<u>\$ 595,648</u>	<u>\$ 635,713</u>

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Nevro Corp.**  
**Condensed Consolidated Statements of Operations and Comprehensive Loss**  
**(unaudited)**  
**(in thousands, except share and per share data)**

	Three Months Ended			Nine Months Ended		
	September 30,		2024	September 30,		2023
	2024	2023		2024	2023	
Revenue	\$ 96,910	\$ 103,862	\$ 302,970	\$ 308,998		
Cost of revenue <sup>(1)</sup>	32,296	34,346	99,361	100,415		
Gross profit	64,614	69,516	203,609	208,583		
Operating expenses						
Research and development	10,579	13,923	39,524	41,998		
Sales, general and administrative	68,471	81,152	233,571	254,106		
Amortization of intangibles	737	—	2,211	—		
Change in fair value of contingent consideration	(1,307)	—	3,124	—		
Total operating expenses	78,480	95,075	278,430	296,104		
Loss from operations	(13,866)	(25,559)	(74,821)	(87,521)		
Interest income	3,226	3,594	10,323	10,220		
Interest expense	(7,008)	(1,618)	(20,261)	(4,849)		
Change in fair market value of warrants	3,438	—	26,502	—		
Other income (expense), net	(854)	234	(1,147)	(150)		
Loss before income taxes	(15,064)	(23,349)	(59,404)	(82,300)		
Provision for income taxes	280	130	924	932		
Net loss	(15,344)	(23,479)	(60,328)	(83,232)		
Other comprehensive income (loss):						
Changes in foreign currency translation adjustment	1,337	(765)	1,125	77		
Changes in unrealized gains on short-term investments, net	1,239	470	563	865		
Net change in other comprehensive income (loss)	2,576	(295)	1,688	942		
Comprehensive loss	\$ (12,768)	\$ (23,774)	\$ (58,640)	\$ (82,290)		
Net loss per common share, basic and diluted	\$ (0.41)	\$ (0.65)	\$ (1.63)	\$ (2.32)		
Weighted average number of shares used to compute basic and diluted net loss per share	<u>37,324,907</u>	<u>36,142,255</u>	<u>36,911,231</u>	<u>35,882,826</u>		

<sup>(1)</sup> Exclusive of amortization of intangible assets, which is shown separately.

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Nevro Corp.**  
**Condensed Consolidated Statements of Stockholders' Equity**  
**(unaudited)**  
**(in thousands, except share data)**

For the three and nine months ended September 30, 2024

	Shares	Common Stock Amount	Additional			Accumulated Deficit	Other Comprehensive Income (Loss)	Total
			Paid-In Capital	Accumulated Deficit	Stockholders' Equity			
<b>Balances at December 31, 2023</b>	36,361,474	\$ 36	\$ 992,762	\$ (699,410)	\$ (243)	\$ 293,145		
Issuance of common stock upon release of restricted stock units	408,083	—	—	—	—	—	—	—
Shares withheld for tax obligations	(82,727)	—	(1,251)	—	—	—	(1,251)	
Stock based compensation	—	—	12,837	—	—	—	12,837	
Net loss	—	—	—	(25,409)	—	—	(25,409)	
Other comprehensive loss	—	—	—	—	(781)	—	(781)	
<b>Balances at March 31, 2024</b>	36,686,830	\$ 36	\$ 1,004,348	\$ (724,819)	\$ (1,024)	\$ 278,541		
Issuance of common stock upon release of restricted stock units	275,513	—	—	—	—	—	—	—
Shares withheld for tax obligations	(61,316)	—	(662)	—	—	—	(662)	
Issuance of common stock under employee stock purchase plan	303,187	1	2,721	—	—	—	2,722	
Stock based compensation	—	—	13,334	—	—	—	13,334	
Net loss	—	—	—	(19,575)	—	—	(19,575)	
Other comprehensive loss	—	—	—	—	(107)	—	(107)	
<b>Balances at June 30, 2024</b>	37,204,214	\$ 37	\$ 1,019,741	\$ (744,394)	\$ (1,131)	\$ 274,253		
Issuance of common stock upon release of restricted stock units	293,361	—	—	—	—	—	—	—
Shares withheld for tax obligations	(58,020)	—	(360)	—	—	—	(360)	
Stock based compensation	—	—	12,518	—	—	—	12,518	
Net loss	—	—	—	(15,344)	—	—	(15,344)	
Other comprehensive income	—	—	—	—	2,576	—	2,576	
<b>Balances at September 30, 2024</b>	<u>37,439,555</u>	<u>\$ 37</u>	<u>\$ 1,031,899</u>	<u>\$ (759,738)</u>	<u>\$ 1,445</u>	<u>\$ 273,643</u>		

For the three and nine months ended September 30, 2023

	Shares	Common Stock Amount	Additional			Accumulated Deficit	Other Comprehensive Income (Loss)	Total
			Paid-In Capital	Accumulated Deficit	Stockholders' Equity			
<b>Balances at December 31, 2022</b>	35,520,507	\$ 35	\$ 934,132	\$ (607,197)	\$ (3,094)	\$ 323,876		
Issuance of common stock upon release of restricted stock units	243,276	1	(1)	—	—	—	—	—
Shares withheld for tax obligations	(69,763)	—	(2,273)	—	—	—	(2,273)	
Stock based compensation	—	—	13,561	—	—	—	13,561	
Net loss	—	—	—	(35,029)	—	—	(35,029)	
Other comprehensive income	—	—	—	—	1,093	—	1,093	
<b>Balances at March 31, 2023</b>	35,694,020	\$ 36	\$ 945,419	\$ (642,226)	\$ (2,001)	\$ 301,228		
Exercise of common stock options	83,058	—	1,455	—	—	—	1,455	
Issuance of common stock upon release of restricted stock units	185,918	—	—	—	—	—	—	—
Shares withheld for tax obligations	(38,463)	—	(1,080)	—	—	—	(1,080)	
Issuance of common stock under employee stock purchase plan	155,589	—	3,747	—	—	—	3,747	
Stock based compensation	—	—	13,980	—	—	—	13,980	
Net loss	—	—	—	(24,724)	—	—	(24,724)	
Other comprehensive income	—	—	—	—	144	—	144	
<b>Balances at June 30, 2023</b>	36,080,122	\$ 36	\$ 963,521	\$ (666,950)	\$ (1,857)	\$ 294,750		
Issuance of common stock upon release of restricted stock units	151,148	—	—	—	—	—	—	—
Shares withheld for tax obligations	(44,224)	—	(1,012)	—	—	—	(1,012)	
Stock based compensation	—	—	15,702	—	—	—	15,702	
Net loss	—	—	—	(23,479)	—	—	(23,479)	
Other comprehensive loss	—	—	—	—	(295)	—	(295)	
<b>Balances at September 30, 2023</b>	<u>36,187,046</u>	<u>\$ 36</u>	<u>\$ 978,211</u>	<u>\$ (690,429)</u>	<u>\$ (2,152)</u>	<u>\$ 285,666</u>		

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Nevro Corp.**  
**Condensed Consolidated Statements of Cash Flows**  
**(unaudited)**  
**(in thousands)**

	Nine Months Ended September 30,	
	2024	2023
<b>Cash flows from operating activities</b>		
Net loss	\$ (60,328)	\$ (83,232)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	5,974	4,935
Amortization of operating lease assets	2,625	3,330
Stock-based compensation expense	38,682	43,249
Amortization of intangibles	2,211	—
Amortization of premium (accretion of discount) on short-term investments	(3,186)	(2,766)
Provision for doubtful accounts	936	391
Write-down of inventory	1,515	2,969
Loss on disposal of equipment	328	—
Amortization of debt issuance costs	2,898	935
Non-cash interest expense	8,230	—
Change in fair value of warrants	(26,502)	—
Change in fair value of contingent consideration	3,124	—
Unrealized (gains) losses on foreign currency transactions	459	(492)
Changes in operating assets and liabilities		
Accounts receivable	7,547	9,350
Inventories	(3,672)	(24,834)
Prepaid expenses and other current assets	(1,179)	(362)
Other assets	(591)	208
Accounts payable	(1,047)	2,050
Accrued liabilities	(14,829)	(1,554)
Other long-term liabilities	(1,229)	(4,083)
Net cash provided by (used in) operating activities	(38,034)	(49,906)
<b>Cash flows from investing activities</b>		
Purchases of short-term investments	(134,442)	(169,869)
Proceeds from maturity of short-term investments	151,640	172,410
Investment in private company	—	(1,900)
Payment for acquisition of business, net of cash acquired	(45)	—
Purchases of property and equipment	(7,794)	(6,732)
Net cash provided by (used in) investing activities	9,359	(6,091)
<b>Cash flows from financing activities</b>		
Convertible notes debt issuance costs	(328)	—
Minimum tax withholding paid on behalf of employees for net share settlement	(2,267)	(4,366)
Payment of contingent consideration established in purchase accounting	(4,964)	—
Proceeds from issuance of common stock to employees	2,722	5,202
Net cash provided by (used in) financing activities	(4,837)	836
Effect of exchange rate changes on cash and cash equivalents	1,277	(57)
Net increase (decrease) in cash, cash equivalents and restricted cash	(32,235)	(55,218)
<b>Cash, cash equivalents and restricted cash</b>		
Cash, cash equivalents and restricted cash at beginning of period	104,823	120,979
Cash, cash equivalents and restricted cash at end of period	<u>\$ 72,588</u>	<u>\$ 65,761</u>
<b>Significant non-cash transactions</b>		
Purchases of property and equipment in accounts payable	\$ 328	\$ 728
Remeasurement of operating lease right-of-use assets for lease modification	\$ 15,457	\$ —

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Nevro Corp.**  
**Notes to Condensed Consolidated Financial Statements**  
**(unaudited)**

## **1. Summary of Significant Accounting Policies**

### **Basis of Presentation**

The accompanying interim condensed consolidated financial statements as of September 30, 2024 and for the three and nine months ended September 30, 2024 and 2023, and the related interim information contained within the notes to the financial statements, are unaudited. The unaudited interim condensed consolidated financial statements (the condensed consolidated financial statements) have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and on the same basis as the audited financial statements included on the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the Annual Report) filed with the Securities and Exchange Commission (SEC) on February 23, 2024. The condensed consolidated financial statements are prepared in U.S. dollars and include the Company's accounts and those of its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company's financial position as of September 30, 2024, the results of its operations for the three and nine months ended September 30, 2024 and 2023 and the consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023. All such adjustments are of a normal and recurring nature. The interim financial data as of September 30, 2024 is not necessarily indicative of the results to be expected for the year ending December 31, 2024, or for any future period.

The consolidated balance sheet as of December 31, 2023 was derived from the audited financials as of that date. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2023 included in the Annual Report.

### **Use of Estimates**

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by management. Actual results may differ from those estimates under different assumptions or conditions.

### **Foreign Currency Translation**

Unrealized foreign exchange gains and losses from the remeasurement of assets and liabilities denominated in currencies other than the functional currency of the reporting entity are recorded in other income (expense), net. Additionally, realized gains and losses resulting from transactions denominated in currencies other than the local currency are recorded in other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The Company recorded net unrealized and net realized foreign currency transaction gains (losses) during the periods presented as follows (in thousands):

	Three Months Ended September 30, 2024		Nine Months Ended September 30, 2024	
	2024	2023	2024	2023
Net unrealized foreign currency gain (loss)	\$ (793)	\$ 547	\$ (597)	\$ 402
Net realized foreign currency gain (loss)	(11)	(259)	(399)	(396)

### **New Accounting Pronouncements Not Yet Adopted**

In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-09 (Topic 740): *Income Taxes: Improvements to Income Tax Disclosures* which expands the existing rules on income tax disclosures. This update requires entities to disclose specific categories in the tax rate reconciliation, provide additional information for reconciling items that meet a quantitative threshold and disclose additional information about income taxes paid on an annual basis. The new disclosure requirements are effective for fiscal years beginning after December 15, 2024. The Company plans to adopt ASU 2023-09

and related updates on January 1, 2025. The Company is currently evaluating the impact that the updated standard will have on its financial statement disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): *Improvements to Reportable Segment Disclosures* which requires disclosure of incremental segment information on an interim and annual basis and provides new segment disclosure requirements for entities with a single reportable segment. ASU 2023-07 is effective for all public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company will begin including additional financial statement disclosures in accordance with ASU 2023-07 in its Annual Report on Form 10-K for the year ending December 31, 2024.

## 2. Revenue

The following table presents revenue by geography, based on the billing address of the customer (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2024	2023	September 30, 2024	2023
United States	\$ 83,898	\$ 89,760	\$ 261,630	\$ 265,042
International	13,012	14,102	41,340	43,956
<b>Total revenue</b>	<b>\$ 96,910</b>	<b>\$ 103,862</b>	<b>\$ 302,970</b>	<b>\$ 308,998</b>

The United States is the only country that accounts for 10% or more of the revenue during the periods presented:

	Three Months Ended		Nine Months Ended	
	September 30, 2024	2023	September 30, 2024	2023
United States	87%	86%	86%	86%

There were no customers that accounted for 10% or more of the Company's revenue for each of the three and nine months ended September 30, 2024 and 2023. Additionally, there were no customers that accounted for 10% or more of the Company's accounts receivable balance as of September 30, 2024 and December 31, 2023. For the three and nine months ended September 30, 2024, the Company recognized bad debt expenses of \$0.4 million and \$0.9 million, respectively. For the three and nine months ended September 30, 2023, the Company recognized bad debt expenses of \$0 and \$0.4 million, respectively.

## 3. Lease Accounting

The Company has operating leases for office space, a manufacturing facility, warehouse, research and development facilities and equipment. Leases with terms of 12 months or less are not recorded on the balance sheet, as the related lease expenses are recognized on a straight-line basis over the lease term. The Company accounts for lease components (such as fixed payments) separately from non-lease components (such as common area expenses).

The weighted average lease terms and discounts rates are as follows:

	September 30, 2024	December 31, 2023
<b>Operating Lease Term and Discount Rate</b>		
Weighted-average remaining lease term	7.17 years	2.86 years
Weighted-average discount rate	7.0%	7.0%

As of September 30, 2024, the maturity of lease liabilities are as follows (in thousands):

	Operating Leases
2024, remaining months	\$ 362
2025	545
2026	5,323
2027	5,508
2028	5,698
Thereafter	18,070
 Total lease payments	35,506
Less: Interest	(10,842)
 Present value of lease liabilities	<u><u>\$ 24,664</u></u>

Lease payments in 2025 are net of a tenant improvement allowance of \$4.7 million that the Company expects to receive in 2025.

Supplemental lease cost information are as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Operating lease cost	\$ 1,160	\$ 1,342	\$ 3,723	\$ 4,027

Supplemental balance sheet information are as follows (in thousands):

	September 30, 2024		December 31, 2023	
	2024	2023	2024	2023
<b>Operating Leases:</b>				
Operating lease assets	<u><u>\$ 21,776</u></u>	<u><u>\$ 8,944</u></u>		
Other current liabilities	\$ 343	\$ 5,722		
Long term operating lease liabilities	24,321	4,634		
<b>Total operating lease liabilities</b>	<u><u>\$ 24,664</u></u>	<u><u>\$ 10,356</u></u>		

Supplemental cash flow information are as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
<b>Cash paid for amounts included in the measurement of lease liabilities:</b>				
Operating cash flow from operating leases	\$ 129	\$ 1,523	\$ 2,248	\$ 4,497

See Note 6 for further details of the Company's lease commitments.

#### 4. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

- Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities.
- Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

- Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the Company's financial assets and liabilities that were measured at fair value on a recurring basis, by level, within the fair value hierarchy (in thousands):

Balance as of September 30, 2024	Level 1	Level 2	Level 3	Total
<b>Assets:</b>				
Cash equivalents and short-term investments				
Money market funds (i)	\$ 50,468	\$ —	\$ —	\$ 50,468
Agency bonds (ii)	—	19,965	—	19,965
Treasury bonds (ii)	185,091	—	—	185,091
Total assets	<u>\$ 235,559</u>	<u>\$ 19,965</u>	<u>\$ —</u>	<u>\$ 255,524</u>
<b>Liabilities:</b>				
Warrant liability	\$ —	\$ —	\$ 2,238	\$ 2,238
Contingent consideration	—	—	15,413	15,413
Total liabilities	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 17,651</u>	<u>\$ 17,651</u>
Balance as of December 31, 2023	Level 1	Level 2	Level 3	Total
<b>Assets:</b>				
Cash equivalents and short-term investments				
Money market funds (i)	\$ 82,886	\$ —	\$ —	\$ 82,886
Agency bonds (ii)	—	99,054	—	99,054
Commercial paper (ii)	—	22,374	—	22,374
Corporate notes (ii)	—	3,490	—	3,490
Treasury bonds (ii)	93,588	—	—	93,588
Total assets	<u>\$ 176,474</u>	<u>\$ 124,918</u>	<u>\$ —</u>	<u>\$ 301,392</u>
<b>Liabilities:</b>				
Warrant liability	\$ —	\$ —	\$ 28,739	\$ 28,739
Contingent consideration	—	—	22,093	22,093
Total liabilities	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 50,832</u>	<u>\$ 50,832</u>

(i) Included in cash and cash equivalents on the condensed consolidated balance sheets.

(ii) Included in short-term investments on the condensed consolidated balance sheets.

#### Cash Equivalents and Short-Term Investments

The Company's money market funds are classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets for identical securities. The Company's short-term investments are comprised of agency bonds, commercial paper, corporate notes and treasury bonds. All short-term investments have been classified within Level 1 or Level 2 of the fair value hierarchy because of the sufficient observable inputs for revaluation. The Company's Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry-standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs.

#### Convertible Senior Notes

As of September 30, 2024 and December 31, 2023, the fair value of the 2.75% convertible senior notes due 2025 (the 2025 Notes) was \$37.3 million and \$35.6 million, respectively. The fair value was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy (See Note 7 for additional information regarding the 2025 Notes).

#### Warrant Liability

In November 2023, the Company entered into a Credit Agreement and Guaranty (the Braidwell Credit Agreement) with Braidwell LP (together with its affiliates, Braidwell). In connection with the Braidwell Credit Agreement, the Company issued

warrants (the Braidwell Warrants) to Braidwell to purchase an aggregate of approximately 2.58 million shares of the Company's common stock.

The Braidwell Warrants are valued using the Black Scholes valuation model and are considered Level 3 in the fair value hierarchy. As of September 30, 2024 and December 31, 2023, the fair value of the Braidwell Warrants was \$2.2 million and \$28.7 million, respectively. Assumptions for the warrant liability are as follows:

	September 30, 2024	December 31, 2023
Expected term (in years)	5.2	6.0
Expected volatility	53%	53%
Risk-free interest rate	3.25%	3.50%
Dividend yield	0%	0%

#### Contingent Consideration

In connection with the Company's acquisition of Interventional Pain Technologies, Inc. (Vyrsa) in the fourth quarter of 2023, the Company is subject to certain contingent consideration. Changes in the fair value of the contingent consideration liability for the nine months ended September 30, 2024 were as follows (in thousands):

Balance as of December 31, 2023	\$ 22,093
Change in fair value of contingent consideration	3,124
Contingent consideration payments	(9,804)
Balance as of September 30, 2024	<u>\$ 15,413</u>

Upon the achievement of the regulatory approval milestone in the three months ended March 31, 2024, the Company accrued an additional \$5.0 million and made contingent consideration payments of \$9.8 million.

The regulatory approval milestone and product development milestone consideration are valued using the probability-weighted average discount cash flow model, and the revenue milestone consideration is valued using the Monte Carlo simulation model. The contingent consideration is considered Level 3 in the fair value hierarchy. As of September 30, 2024, the fair value of the contingent consideration related to the product development and revenue milestones were \$1.7 million and \$13.5 million, respectively. As of December 31, 2023, the fair value of the contingent consideration related to the regulatory approval, product development and revenue milestones were \$5.0 million, \$1.7 million and \$15.5 million, respectively.

Significant unobservable inputs for the contingent consideration are as follows:

Contingent Liability	Fair Value at September 30, 2024	Valuation Technique	Unobservable Input	Range
Product Development Milestone	\$1,716	Probability-Weighted Average Discount Cash Flow	Probability of Payment	75%
Revenue Milestone	\$13,501	Monte Carlo Simulation	Risk-Free Rate	4.2% - 4.8%

Contingent Liability	Fair Value at December 31, 2023	Valuation Technique	Unobservable Input	Range
Regulatory Approval Milestone	\$4,964	Probability-Weighted Average Discount Cash Flow	Probability of Payment Risk-Free Rate Credit Spread	80% 5.2% — 5.3% 4.3%
Product Development Milestone	\$1,677	Probability-Weighted Average Discount Cash Flow	Projected Year of Payment Probability of Payment Risk-Free Rate Credit Spread	2024 50% 4.9% — 5.1% 4.3%
Revenue Milestone	\$15,452	Monte Carlo Simulation	Projected Year of Payment Discount Rate Revenue Volatility	2024 — 2025 8.7% — 9.3% 17.0%
			Projected Year of Payment	2025 — 2027

## 5. Balance Sheet Components

### Cash and Cash Equivalents

The Company considers all highly-liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include money market funds in the amount of \$50.5 million and \$82.9 million as of September 30, 2024 and December 31, 2023, respectively. As of September 30, 2024 and December 31, 2023, the Company's cash equivalents were held at institutions in the United States and include deposits in a money market fund which was unrestricted as to withdrawal or use. The Company also held cash in foreign banks of approximately \$13.8 million at September 30, 2024 and \$9.4 million at December 31, 2023 that was not insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.

### Investments

The Company measures its cash equivalents and short-term investments at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income within stockholders' equity. The Company regularly reviews its investments and evaluates the current expected credit loss by considering factors such as historical experience, market data, and the near-term prospects of the investee. The following is a summary of the gross unrealized gains and unrealized losses on the Company's investment securities, excluding investments in money market funds (in thousands):

	September 30, 2024				
	Amortized Cost	Gross Unrealized Holding Gains	Gross Unrealized Holding Losses	Aggregate Fair Value	
<b>Investment Securities</b>					
Agency bonds	\$ 19,903	\$ 62	\$ —	\$ 19,965	
Treasury bonds	184,333	770	(12)	185,091	
<b>Total securities</b>	<b>\$ 204,236</b>	<b>\$ 832</b>	<b>\$ (12)</b>	<b>\$ 205,056</b>	

	December 31, 2023				
	Amortized Cost	Gross Unrealized Holding Gains	Gross Unrealized Holding Losses	Aggregate Fair Value	
<b>Investment Securities</b>					
Agency bonds	\$ 99,076	\$ 68	\$ (90)	\$ 99,054	
Commercial paper	22,369	5	—	22,374	
Corporate notes	3,491	—	(1)	3,490	
Treasury bonds	93,312	317	(41)	93,588	
<b>Total securities</b>	<b>\$ 218,248</b>	<b>\$ 390</b>	<b>\$ (132)</b>	<b>\$ 218,506</b>	

Realized gains or losses and other-than-temporary impairments, if any, on available-for-sale securities are reported in other income (expense), net as incurred. The cost of securities sold is determined based on the specific identification method. The amount of realized gains and realized losses on investments recorded for the periods presented has not been material.

The contractual maturities of the Company's investment securities as of September 30, 2024 were as follows (in thousands):

	Amortized Cost	Fair Value
Amounts maturing within one year	\$ 133,135	\$ 133,483
Amounts maturing after one year through five years	71,101	71,573
<b>Total investment securities</b>	<b>\$ 204,236</b>	<b>\$ 205,056</b>

#### Inventories (in thousands)

	September 30, 2024	December 31, 2023
Raw materials	\$ 56,428	\$ 64,974
Work in process	7,338	2,149
Finished goods	56,646	51,553
<b>Total inventories</b>	<b>\$ 120,412</b>	<b>\$ 118,676</b>

Inventories are stated at the lower of cost or net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-out basis. Net realizable value is determined as the prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company regularly reviews inventory quantities compared to forecasted sales to record a provision for excess and obsolete inventory when appropriate. Inventory write-downs are recorded for excess and obsolete inventory. The Company estimates forecasted sales by considering product acceptance in the marketplace, customer demand, historical sales, product obsolescence and technological innovations.

The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that has been used to value the inventory. The Company also periodically evaluates inventory quantities in consideration of actual loss experience. For the three months ended September 30, 2024 and 2023, the Company recognized a write-down of \$0.8 million and \$0.1 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company had write-downs of \$1.5 million and \$3.0 million, respectively.

#### Property and Equipment, Net (in thousands)

	September 30, 2024	December 31, 2023
Laboratory and manufacturing equipment	\$ 15,152	\$ 15,414
Computer equipment and software	16,233	15,451
Internally developed software	12,366	8,831
Furniture and fixtures	4,781	4,745
Leasehold improvements	11,099	10,924
Construction in process	5,875	4,865
<b>Total</b>	<b>65,506</b>	<b>60,230</b>
Less: Accumulated depreciation and amortization	(40,578)	(35,662)
<b>Property and equipment, net</b>	<b>\$ 24,928</b>	<b>\$ 24,568</b>

The Company recognized depreciation and amortization expense on property and equipment as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30, 2024	2023	September 30, 2024	2023
Depreciation and amortization expense	\$ 1,908	\$ 1,723	\$ 5,974	\$ 4,935

#### Accrued Liabilities (in thousands)

	September 30, 2024	December 31, 2023
Accrued payroll and related expenses	\$ 20,645	\$ 31,715
Accrued professional fees	619	2,909
Accrued taxes	2,054	1,482
Accrued clinical and research expenses	604	752
Accrued interest	1,495	1,123
Accrued warranty	2,500	1,531
Accrued other	7,026	5,785
Total accrued liabilities	<u>\$ 34,943</u>	<u>\$ 45,297</u>

#### 6. Commitments and Contingencies

##### Operating Leases

In March 2015, the Company entered into a lease agreement for approximately 50,000 square feet of office space located in Redwood City, California for a period beginning on June 30, 2015 and ending in May 2022, with initial annual payments of approximately \$2.0 million, increasing to \$2.4 million annually during the final year of the lease term. In December 2016, the Company entered into a first amendment to the lease for an additional approximately 50,000 square feet of office space adjacent to the premises under the original lease (the Expansion Premises), with initial annual payments of \$1.2 million, increasing to \$2.9 million in the final year of the amended lease term. The lease for the Expansion Premises commenced on June 1, 2018, and includes an expiration date of May 31, 2025. The first amendment extended the lease term for the original premises to terminate on the same date as the Expansion Premises. In April 2024, the Company entered into a second amendment which reduced the total office space to approximately 78,000 square feet, beginning on June 1, 2024 and ending on December 31, 2031, with initial annual payments of approximately \$3.0 million, increasing to approximately \$5.7 million during the final year of the lease term. Pursuant to the second lease amendment, the landlord provided the Company with a tenant improvement allowance of up to \$4.7 million. The amendment increased the right-of-use asset and lease liability by \$15.5 million.

The Company entered into a separate non-cancellable facility lease for warehouse space beginning on March 1, 2017 through February 28, 2022, under which it is obligated to pay approximately \$0.4 million in lease payments over the term of the lease. In October 2021, the Company entered into a first amendment of the warehouse lease, which extends the lease term to terminate on May 31, 2025 and under which the Company is obligated to pay approximately \$0.4 million over the term of the extension period.

In August 2020, the Company entered into a lease for approximately 35,411 square feet of space for a manufacturing facility in Costa Rica to begin in April 2021 and to last through June 2031, under which it is obligated to pay approximately \$3.9 million in lease payments over the term of the lease. On the commencement date in April 2021, the Company classified and measured the lease, resulting in the recording of operating assets of \$2.9 million and operating lease liabilities of \$2.9 million.

In September 2024, the Company entered into a lease for 13,623 square feet of office space located in Plymouth Meeting, Pennsylvania to commence on the later of December 1, 2024 or completion of the landlord's building improvements. The lease is through February 2033. Pursuant to the terms of the lease, the Company is obligated to pay \$2.0 million over the term of the lease. The Company expects to record operating assets of \$0.9 million and operating lease liabilities of \$0.9 million on the lease commencement date.

See Note 3 for further discussion on Lease Accounting.

##### Warranty Obligations

The Company provides a limited one- to five-year warranty and warrants that its products will operate substantially in conformity with product specifications. The Company records an estimate for the provision for warranty claims in cost of revenue when the related revenues are recognized. This estimate is based on historical and anticipated rates of warranty claims, the cost per claim and the number of units sold. The Company regularly assesses the adequacy of its recorded warranty obligations and adjusts the amounts as necessary. Activities related to warranty obligations were as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2024	2023	2024	2023
Beginning balance	\$ 2,200	\$ 1,349	\$ 1,531	\$ 866
Provision for warranty	1,489	1,051	4,516	3,899
Utilization	(1,189)	(923)	(3,547)	(3,288)
Ending balance	<u>\$ 2,500</u>	<u>\$ 1,477</u>	<u>\$ 2,500</u>	<u>\$ 1,477</u>

### Supply Agreements

The Company has entered into supply agreements with certain suppliers that require certain minimum annual purchase agreements. As of September 30, 2024, the Company had minimum annual purchase commitments of \$1.1 million due for the remainder of 2024 and \$4.9 million due in 2025. In addition, the Company renegotiated a supplier contract resulting in a one-time \$6.0 million fee, recorded in accrued liabilities and expensed to cost of revenue as of June 30, 2024. The Company paid \$4.0 million of such renegotiation fee during the three months ended September 30, 2024 and the remaining \$2.0 million is due in 2025. The renegotiation reduced the Company's future purchase commitments enabling the company to accelerate the move of inventory production to its Costa Rica facility.

### Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities related to, for example, employment matters and patent issues. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. When determining the estimated loss or range of loss, significant judgment is required. In July 2023, the Company entered into a stock and note purchase agreement and agreed to purchase \$1.0 million in notes and \$2.0 million in total stock whereby such purchases are contingent upon meeting certain future milestones. As of September 30, 2024, such milestones have not been met.

### Indemnification

The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company's technology. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made.

The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has director and officer insurance coverage that reduces the Company's exposure and enables the Company to recover a portion of any future amounts paid. The Company believes the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

### Legal Matters

The Company is and may from time to time continue to be involved in various legal proceedings to defend its intellectual property, including several pending European patent oppositions at the European Patent Office (EPO) initiated by the Company's competitors Medtronic and Boston Scientific. In addition, the Company is and may from time to time also be involved in various legal proceedings, such as employment matters, product liability matters, and professional liability matters, which the Company does not deem to be material to its business and condensed consolidated financial statements at this stage.

#### Flathead Partners Litigation/Arbitration

On July 15, 2022, the Company filed a lawsuit in the U.S. District Court for the Northern District of California for breach of contract against Flathead Partners, LLC, the Mayo Foundation for Medical Education and Research, and Mayo Clinic Ventures (herein referred to as "Flathead Partners"). The Company's suit alleged that Flathead Partners breached the 2006 license agreement between the Company and the Mayo Clinic (referred to in the Company's 10-K filing as the "Mayo License"), when Flathead Partners unilaterally asserted control of pending U.S. Patent Application 16/286,389 (the "389 Application"), which is subject to the Mayo

License. The suit sought to enjoin the Flathead Partners from taking any action at the U.S. Patent Office with respect to the '389 Application, and to thereafter engage in an arbitration as called for in the Mayo License. On July 27, 2022, the Flathead Partners agreed to enter into an arbitration to determine which party shall have control of prosecution of the '389 Application, and whether there are ongoing royalty obligations under the Mayo License. Therefore, Nevro dismissed the lawsuit in the Northern District of California. The parties then engaged in an arbitration. An arbitration hearing was held during the week of September 11, 2023, and a ruling was issued on April 8, 2024 requiring that Flathead Partners transfer back to the Company the power to control and direct prosecution of the '389 Application and its patent family. The April 8, 2024 ruling also concluded that Nevro did not owe Flathead Partners royalties under the Mayo License. More specifically, the Arbitrator found that Flathead Partners had breached the Mayo License, and that the Company had not breached the Mayo License. The arbitrator awarded the Company (i) damages, paid by Flathead Partners in May 2024; (ii) the Company's attorneys' fees and costs for the Northern District of California litigation; and (iii) prejudgment interest at a rate of 10%, with prejudgment interest running from June 1, 2022 paid by Flathead Partners in September 2024. As a result, the Company recorded \$0.8 million and \$1.0 million as a credit to sales, general and administrative expense for the three and nine months ended September 30, 2024, respectively.

#### Civil Investigative Demand

In December 2022, the Company received a civil investigative demand (CID) pursuant to the federal False Claims Act from the United States Attorney's Office for the Northern District of California seeking information relating to the Company's spinal cord stimulation system (SCS System). The CID primarily relates to marketing, promotion and billing practices, not the therapeutic or safety attributes of the Company's SCS System. The Company maintains rigorous policies and procedures designed to promote compliance with the federal False Claims Act and other regulatory requirements, and is cooperating in this matter and providing the requested information.

#### **7. Debt**

##### **2025 Notes and Convertible Note Hedge and Warrant Transactions**

During the three months ended September 30, 2024, the conditions allowing holders of the 2025 Notes to convert were not met. Therefore, the 2025 Notes were not convertible during the three months ended September 30, 2024. As of September 30, 2024, the if-converted value of the 2025 Notes did not exceed the principal value of those notes.

The net carrying amount of the liability of the 2025 Notes was as follows (in thousands):

	September 30, 2024	December 31, 2023
Principal	\$ 38,038	\$ 38,038
Unamortized issuance cost	(132)	(326)
<b>Net carrying amount</b>	<b>\$ 37,906</b>	<b>\$ 37,712</b>

The following table sets forth the interest expense recognized related to the 2025 Notes (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2024	2023	2024	2023
Contractual interest expense	\$ 261	\$ 1,305	\$ 785	\$ 3,914
Amortization of debt issuance costs	65	313	194	935
<b>Total interest expense</b>	<b>\$ 326</b>	<b>\$ 1,618</b>	<b>\$ 979</b>	<b>\$ 4,849</b>

#### **Credit Agreement with Braidwell LP**

The Braidwell Credit Agreement provides for a term loan facility in the amount of \$200.0 million, which was funded in its entirety in November 2023. Loans borrowed pursuant to the Braidwell Credit Agreement (the Braidwell Term Loans) bear interest at a rate per annum equal to Term Secured Overnight Financing Rate (as defined in the Braidwell Credit Agreement and with a floor of 3.50%) plus 5.25%. At the option of the Company, a portion of the interest payable on the Braidwell Term Loans equal to (i) (a) on or prior to the first anniversary of the Closing Date (as defined in the Braidwell Credit Agreement), 5.25%, (b) following the first anniversary of the Closing Date and on or prior to the third anniversary of the Closing Date, 2.50% and (c) following the third anniversary of the Closing Date, 1.50%, may be paid in-kind rather than in cash. The portion of the interest payable that the Company elects to be paid-in-kind results in an increase to the principal of the Braidwell Term Loans, which for the three and nine months

ended September 30, 2024 was \$2.8 million and \$8.2 million, respectively. The Braidwell Term Loans do not amortize, and have a maturity date of November 30, 2029. As of September 30, 2024, the Company was in compliance with covenants under the Braidwell Credit Agreement.

The net carrying amount of the liability of the Braidwell Term Loans was as follows (in thousands):

	September 30, 2024	December 31, 2023
Principal	\$ 216,031	\$ 207,801
Unamortized issuance cost	(31,667)	(34,042)
Net carrying amount	<u>\$ 184,364</u>	<u>\$ 173,759</u>

The following table sets forth the interest expense recognized related to the Braidwell Term Loans (in thousands):

	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2024
Contractual interest expense	\$ 5,716	\$ 16,581
Amortization of debt issuance costs	966	2,702
Total interest expense	<u>\$ 6,682</u>	<u>\$ 19,283</u>

## 8. Goodwill and Intangible Assets

Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identifiable intangible assets acquired. The gross carrying amount of goodwill was \$38.2 million as of September 30, 2024 and December 31, 2023.

The following table presents details of the Company's intangible assets (in thousands):

	September 30, 2024		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
<b>Intangible assets with finite lives:</b>			
Developed technology	\$ 26,800	\$ (2,234)	\$ 24,566
Customer relationships	800	(222)	578
<b>Total</b>	<u>\$ 27,600</u>	<u>\$ (2,456)</u>	<u>\$ 25,144</u>
	December 31, 2023		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
<b>Intangible assets with finite lives:</b>			
Developed technology	\$ 26,800	\$ (223)	\$ 26,577
Customer relationships	800	(23)	777
<b>Total</b>	<u>\$ 27,600</u>	<u>\$ (246)</u>	<u>\$ 27,354</u>

Future amortization expense of these intangibles assets as of September 30, 2024 is as follows (in thousands):

	Future Amortization Expense
2024, remaining months	\$ 737
2025	2,947
2026	2,924
2027	2,680
2028	2,680
Thereafter	13,176
<b>Total future amortization expense</b>	<u>\$ 25,144</u>

## 9. Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees in accordance with Accounting Standards Codification (ASC) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a

fair value-based method, for costs related to all share-based payments including stock options. The Company estimates forfeitures expected to occur to determine the amount of compensation cost recognized in each period.

In addition to restricted stock units, the Company grants performance stock units (PSUs) to certain members of the management team. These PSUs vest over a three-year period, subject to continued service, and are based on (1) the total shareholder return (TSR) of the Company's common stock price compared to the S&P Healthcare Equipment Select Industry Index (the Index) over a two-year period or (2) specific revenue targets over a two-year performance period. Additionally, in 2022, the Company made PSU grants to its then CEO that included attainment criteria that required the Company's stock price to reach certain pre-specified stock prices. Since TSR and stock price attainment are considered market conditions, the PSUs based on TSR and stock price attainment have fair values that are determined at the grant date using the Monte Carlo simulation model, with the recorded expense based on fair value. Since revenue targets are considered performance conditions, the PSUs based on revenue targets have a fair value that is equal to the closing stock price on the grant date, with the recorded expense based on the fair value and the probability of achievement, which is reassessed at each reporting period. As of September 30, 2024, the probability of achievement was estimated to be 94% for the PSU's granted in 2024, 90% to 92% for the PSU's granted in 2023, and 94% for the PSU's granted in 2022.

No PSU grants were awarded in the three months ended September 30, 2024. The PSU grant activity is as follows:

	Three Months Ended			Nine Months Ended		
	September 30, 2024		Weighted Average Fair Value	September 30, 2024		Weighted Average Fair Value
	Shares	Weighted Average Fair Value		Shares	Weighted Average Fair Value	
Total shareholder return	—	\$ -		245,833	\$ 20.89	
Revenue targets	—	\$ -		245,844	\$ 15.23	
<b>Total PSUs granted</b>	<b>—</b>	<b>\$ -</b>		<b>491,677</b>	<b>\$ 18.06</b>	

  

	Three Months Ended			Nine Months Ended		
	September 30, 2023		Weighted Average Fair Value	September 30, 2023		Weighted Average Fair Value
	Shares	Weighted Average Fair Value		Shares	Weighted Average Fair Value	
Total shareholder return	12,499	\$ 27.23		185,424	\$ 43.89	
Revenue targets	12,500	\$ 20.11		185,451	\$ 31.39	
<b>Total PSUs granted</b>	<b>24,999</b>	<b>\$ 23.67</b>		<b>370,875</b>	<b>\$ 37.64</b>	

A summary of stock-based compensation expense by line items in the condensed consolidated statements of operations is as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2024	2023	2024	2023
Cost of revenue	\$ 768	\$ 657	\$ 2,130	\$ 1,769
Research and development	1,874	2,388	8,195	7,301
Sales, general and administrative	8,781	10,478	28,357	34,179
<b>Total stock-based compensation expense</b>	<b>\$ 11,423</b>	<b>\$ 13,523</b>	<b>\$ 38,682</b>	<b>\$ 43,249</b>

A summary of pre-tax stock-based compensation expense by category was as follows (in thousands):

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2024	2023	2024	2023
Stock Options	\$ -	\$ -	\$ -	\$ 539
Restricted stock units	10,348	10,776	33,580	34,423
Performance stock units	920	2,510	4,083	6,676
Employee stock purchase plan	155	237	1,019	1,611
<b>Total stock-based compensation expense</b>	<b>\$ 11,423</b>	<b>\$ 13,523</b>	<b>\$ 38,682</b>	<b>\$ 43,249</b>

## 10. Basic and Diluted Net Income (Loss) Per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period, if inclusion of these is dilutive. The Company uses the if-converted method and presumes share settlement for its 2025 Notes when calculating the dilutive effect of these notes. In connection with the offerings of the convertible senior notes, the Company entered into convertible note hedges and warrants. However, the convertible note hedges are not included when calculating potentially dilutive shares since their effect is always anti-dilutive. Warrants were considered anti-dilutive to the extent that their strike price were above the Company's average share price during the period.

The following table summarizes the computation of basic and diluted net loss per share (in thousands, except share and per share data):

	Three Months Ended		Nine Months Ended	
	September 30, 2024	2023	September 30, 2024	2023
Net loss, basic and diluted	\$ (15,344)	\$ (23,479)	\$ (60,328)	\$ (83,232)
Weighted average shares used to compute basic and diluted net loss per share	37,324,907	36,142,255	36,911,231	35,882,826
Net loss per share, basic and diluted	\$ (0.41)	\$ (0.65)	\$ (1.63)	\$ (2.32)

The following potentially dilutive securities outstanding at the end of the periods presented have been excluded from the computation of diluted shares outstanding, as the effect would be anti-dilutive:

	September 30,	
	2024	2023
Unreleased restricted stock and performance stock units	4,367,733	2,795,332
Options to purchase common stock	321,763	386,518
Convertible senior notes	362,267	1,807,141
Warrants related to the issuance of convertible senior notes	1,807,141	1,807,141
Warrants related to term debt	2,587,742	—
Total	<u>9,446,646</u>	<u>6,796,132</u>

## 11. Employee Benefit Plans

### 401(k) Plan

In 2007, the Company adopted a 401(k) plan for its employees whereby eligible employees may contribute up to the maximum amount permitted by the Internal Revenue Code. In June 2016, the Company adopted a policy to match a portion of employee contributions for all qualified employees participating in the 401(k) plan. The Company recorded an expense for matching contributions of \$0.2 million and \$0.3 million for the three months ended September 30, 2024 and 2023, respectively, and \$3.2 million and \$3.4 million for the nine months ended September 30, 2024 and 2023, respectively.

## 12. Restructuring

On January 6, 2024, the Company approved a restructuring plan to accelerate its path to profitability that included laying off 63 employees, which represented approximately 5% of the Company's total number of employees. Operating expenses for the three months ended March 31, 2024 reflected a \$5.5 million restructuring charge, consisting of one-time severance and other termination benefit costs. During the three months ended June 30, 2024 and September 30, 2024, the Company approved additional restructuring steps to further accelerate its path to profitability. Operating expenses for the three months ended June 30, 2024 and September 30, 2024 reflected a restructuring charge of \$4.6 million and \$0.7 million, respectively, consisting of one-time severance and other termination benefit costs. For the nine months ended, September 30, 2024, the Company recognized \$10.8 million of restructuring charge. As of September 30, 2024, substantially all severance and other termination benefit amounts have been paid.

## **Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following management's discussion and analysis of our financial condition and results of operations in conjunction with our unaudited interim condensed consolidated financial statements (the condensed consolidated financial statements) and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q (Quarterly Report) and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2023, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the Annual Report) filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2024.*

### **Special note regarding forward-looking statements**

This report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, those discussed in Part I, Item 1A. *Risk Factors* in our Annual Report as filed with the SEC on February 23, 2024, and those discussed in the section titled "Risk Factors" included under Part II, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

### **Overview**

We are a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. We have developed and commercialized our HFX™ spinal cord stimulation (SCS) platform, which includes the Senza® SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza® HFX iQ™ platform. In September 2024, we announced the FDA approval and limited market release of HFX iQ™ with HFX AdaptivAIT™, a responsive, personalized pain management platform powering the HFX iQ SCS system as our latest addition to the Senza family of products. Our HFX solution is approved to deliver a versatile range of waveforms, including our proprietary, paresthesia-free 10 kHz Therapy. Our 10 kHz Therapy was demonstrated in our SENZA randomized controlled trial (RCT) to be superior to traditional SCS therapy, with 10 kHz Therapy being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. In addition to the original approval of our therapy in back and leg pain, we received approval of our 10 kHz Therapy for the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with painful diabetic neuropathy (PDN) in July 2021 in the United States. We received expanded labeling in non-surgical back pain (NSBP) in January 2022 in the United States. Our SENZA-RCT study, along with our SENZA-PDN clinical study, SENZA-NSRBP clinical study and European studies, represents what we believe is the most robust body of clinical evidence for any SCS therapy. We believe the superiority of 10 kHz Therapy over traditional SCS therapies will allow us to capitalize on and expand the approximately \$2.3 billion global SCS market by treating patients with debilitating chronic pain, including back and leg pain, NSBP and PDN.

We launched Senza commercially in the United States in May 2015, after receiving a label from the U.S. Food and Drug Administration (FDA) supporting the superiority of our 10 kHz Therapy over traditional SCS. The Senza system has been commercially available in certain European markets since November 2010 and in Australia since August 2011. Senza is currently reimbursed by all of the major insurance providers.

In November 2023, we acquired Vyrsa Technologies (Vyrsa), who developed and manufactured a portfolio of Sacroiliac (SI) Joint Fusion devices, expanding our chronic pain portfolio to treat patients diagnosed with SI Joint Dysfunction. With the addition of SI Joint to our pain portfolio, we are able to enter a growing market that builds upon our current customer base, leverages our existing sales force and the addition of the NevroV1™, NevroFix™ and NevroPro™ SI Joint products to our portfolio provides physicians we work with today with another option for treating their chronic pain patients.

In April 2023, we enrolled the first patient in our PDN Sensory study, the first prospective RCT to assess the restoration of neurological function as a primary objective in patients with intractable PDN. The study will enroll up to 236 patients at multiple sites across the United States. Patients will be randomized to conventional medical management (CMM) or 10 kHz Therapy plus CMM.

with optional crossover to the other treatment arm at 6 months if those specific criteria are met. Given that enrollment was proceeding ahead of schedule, we executed a pre-planned pause in enrollment in May 2024 to allow for an interim primary endpoint analysis by an independent statistician of all subjects who are randomized to date. With this milestone, we hope to bring the results of this study to physicians sooner than initially contemplated to potentially accelerate adoption. We still may return to enrolling additional patients in the future.

The tables below set forth our revenue from U.S. and international sales the past ten quarters on a quarterly basis and total revenue for each of the past five full fiscal years.

Revenue from:	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023 (in millions)	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
U.S. sales	\$ 73.2	\$ 89.0	\$ 86.1	\$ 99.8	\$ 82.3	\$ 93.0	\$ 89.8	\$ 101.5	\$ 87.0	\$ 90.7	\$ 83.9
International sales	14.6	15.2	14.3	14.1	14.0	15.8	14.1	14.7	14.9	13.5	13.0
<b>Total sales revenue</b>	<b>\$ 87.8</b>	<b>\$ 104.2</b>	<b>\$ 100.5</b>	<b>\$ 113.8</b>	<b>\$ 96.3</b>	<b>\$ 108.8</b>	<b>\$ 103.9</b>	<b>\$ 116.2</b>	<b>\$ 101.9</b>	<b>\$ 104.2</b>	<b>\$ 96.9</b>

Revenue from:	2019	2020	2021 (in millions)	2022	2023	Nine Months Ended September 30, 2024
U.S. sales	\$ 326.0	\$ 311.9	\$ 326.2	\$ 348.2	\$ 366.6	\$ 261.6
International sales	64.3	50.2	60.7	58.2	58.6	41.4
<b>Total sales revenue</b>	<b>\$ 390.3</b>	<b>\$ 362.0</b>	<b>\$ 386.9</b>	<b>\$ 406.4</b>	<b>\$ 425.2</b>	<b>\$ 303.0</b>

Since our inception, we have financed our operations primarily through equity and debt financings and borrowings under a debt facility. Our accumulated deficit as of September 30, 2024 was \$759.7 million. A significant amount of our capital resources has been used to support the development of our Senza products and our 10 kHz Therapy, and we have also made a significant investment building our U.S. commercial infrastructure and sales force to support our commercialization efforts in the United States. We intend to continue to make significant investments in our U.S. commercial infrastructure, including building out a sales organization that targets physician specialties involved in PDN treatment decisions, as well as in research and development (R&D), and in conducting clinical trials to support our future regulatory submissions. In order to further enhance our R&D efforts, pursue product expansion opportunities or acquire a new business or products that are complementary to our business, we may choose to raise additional funds, which may include future equity and debt financings.

We rely on third-party suppliers for the components of our Senza products. Several of these suppliers are currently single-source suppliers. We are also required to maintain high levels of inventory, and, as a result, we are subject to the risk of inventory obsolescence and expiration, which may lead to inventory impairment charges. Additionally, our dependence on third-party suppliers makes us vulnerable to supply shortage problems and exposes us to greater lead times, increasing our risk of inventory obsolescence. In the third quarter of 2020, we made the strategic decision to vertically integrate the assembly of IPG's, peripherals and various other manufacturing related activities to mitigate our reliance on third-party manufacturers and improve our long-term gross margins. We plan on conducting these manufacturing activities in our facility in Costa Rica, for which our lease began in April 2021. The integration process was completed in mid-2022, and we received approval from the FDA for the manufacture of our Senza system in the Costa Rica facility in September 2022. Even with the commencement of manufacturing in Costa Rica, we have continued to rely on third-party manufacturers as we ramped our factory and in order to provide key components to support the assembly process. We have incurred and may continue to incur significant capital expenditures and implementation costs in our Costa Rica facility.

#### Macroeconomic Conditions

Our business and financial performance are significantly impacted by macroeconomic conditions. Global macroeconomic challenges, such as the effects of the ongoing war between Russia and Ukraine, the conflict in the Middle East, political instability, supply chain constraints, market uncertainty, volatility in exchange rates, inflationary trends, lower consumer confidence and evolving dynamics in the global trade environment have impacted our business and financial performance. Such economic impacts could also impact the decision of patients and customers to seek and undertake elective procedures which would adversely impact our revenue and results of operations.

Furthermore, a recession or market correction resulting from other macroeconomic factors could materially affect our business and the value of our common stock. The occurrence of any such events may lead to reduced disposable income and access to health insurance which could adversely affect the number of products sold as a result of customer and patient reluctance to seek elective care treatment due to increase patient copays and similar financial considerations.

Adverse macroeconomic conditions, other pandemics or international tensions, could also result in significant disruption of global economic conditions and consumer trends, as well as a significant disruption in financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity, including our ability to repay our 2025 Notes and the Braidwell Term Loans. Our ability to repay the 2025 Notes and the Braidwell Term Loans could also be adversely impacted by higher interest rates which could make it more difficult to access capital on favorable terms, or at all.

### **Important Factors Affecting our Results of Operations**

We believe that the following factors have impacted, and we expect will continue to impact, our results of operations.

#### **Macroeconomic Environment**

The global economy is experiencing uncertainty around inflationary pressures and interest rates, supply chain issues, recession fears and lower consumer confidence as a result of current macroeconomic environment and geopolitical conditions. Higher interest rates and capital costs, increased costs of labor and volatile currency exchange rates are creating additional economic challenges. These conditions may cause patients to delay their decisions to seek medical elective procedures.

#### **Importance of Physician Awareness and Acceptance of Our Products**

We continue to invest in programs to educate physicians who treat chronic back and leg pain about the advantages of our products. This requires significant commitment by our marketing team and sales organization, and can vary depending upon the physician's practice specialization, personal preferences and geographic location.

#### **Reimbursement and Coverage Decisions by Third-Party Payors**

Healthcare providers in the United States generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to cover and reimburse all or part of the cost of our products and the related implant procedure for patients. The revenue we are able to generate from sales of our products depends in large part on the availability of reimbursement from such payors. Currently, there is a National Coverage Determination (NCD 160.7) that provides the conditions for coverage by Medicare as a late (if not last) resort for patients with chronic intractable pain. This broad coverage is inclusive of all our approved indications such as Failed Back Surgery Syndrome, Painful Diabetic Neuropathy (PDN), and Non Surgical Refractory Back Pain (NSBP). The local Medicare Administrative Contractors (MACs) cannot be more restrictive in coverage than this NCD. Only one MAC, Noridian, still has a Local Coverage Determination (LCD) which does not limit based on indications but does have a finite list of diagnosis they deem to meet medical necessity criteria. Decisions of coverage and reimbursement for Senza and the related implant procedure from private health insurance providers can vary. In general, these decisions require that such payors perform analyses to determine if the procedure is medically necessary and if our technology is a covered benefit under the patient's existing policies. These payors may deny pre-service prior authorization if they determine that the device or procedure is not medically necessary for the patient and used in accordance with the payor's coverage policy. Pre-service denials are able to be appealed through various channels with medical necessity decisions often made by third-parties based on an individual patient's medical history.

A significant component of our commercial efforts includes working with private payors to ensure positive coverage decisions for our products. For our traditional chronic back and leg pain market, we believe that favorable coverage and reimbursement for procedures using our products from Medicare and certain commercial payors, such as Aetna, Cigna, Humana, Blue Cross Blue Shield (BCBS) and United Healthcare, have contributed to our increase in revenue to date. Although the largest commercial payors and Medicare cover procedures using Senza, there can be no assurance that all private health insurance plans will cover the therapy. While Medicare, through both national and local coverage policies, currently provides coverage for NSBP, most commercial payors do not yet have coverage policies for NSBP and may consider coverage for this indication on a case-by-case basis.

Effective April 14, 2024, Carelon and Anthem BCBS updated their medical policy to explicitly cover PDN. These health plans cover approximately 44 million covered lives and brings total PDN coverage to over 250 million covered lives.

With respect to both PDN and NSBP, there are still some payors that have not yet updated their policies to expressly cover SCS procedures, including in the case of PDN, Cigna and Humana. Nevro's Patient Access team supports case-by-case approvals for these indications with these payors, however, a significant number of negative coverage and reimbursement decisions by private insurers may impair our ability or delay our ability to grow our revenue.

We are working to expand payor coverage to include the use of our 10 kHz Therapy for the management of PDN and NSBP. This effort could be costly and could take many years to gain broad acceptance, and there can be no guarantee that it will be successful.

### **Inventory Buildup and Supply Chain Management**

Our products are composed of a substantial number of individual components and, in order to market and sell them effectively, we must maintain high levels of inventory. We have continued to add suppliers to fortify our supply chain and we have maintained increased levels of inventory. As a result, a significant amount of our cash used in operations has been associated with maintaining these levels of inventory. There may also be times in which we determine that our inventory does not meet our product requirements. The manufacturing process for our products requires lengthy lead times, during which components may become obsolete. We may also over or underestimate the quantities of required components, in which case we may expend extra resources or be constrained in the amount of end product that we can produce. Additionally, as we release later generations of products that contain advancements or additional features, the earlier generations may become obsolete. These factors subject us to the risk of inventory obsolescence and expiration, which may lead to inventory impairment charges. The sum of the charges for the items listed above were \$1.5 million for the nine months ended September 30, 2024 and \$2.1 million for the year ended December 31, 2023.

### **Investment in Research and Clinical Trials**

We intend to continue investing in R&D to help our commercialization efforts around and to expand into new indications and chronic pain conditions, as well as develop product enhancements to improve outcomes and enhance the physician and patient experience. For example, we commenced commercial launches of Surpass, our surgical lead product family in early 2017 and Senza II SCS System in late 2017. We launched our Senza Omnia platform, in the United States in late 2019, in Europe during the second quarter of 2020 and in Australia in July 2020. In the first quarter of 2021, we received FDA approvals for our first Senza Omnia upgrade and a new trial stimulator. In July 2021, we received FDA approval of our 10 kHz Therapy for the management of chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with PDN. In January 2022, we received regulatory approval for expanded labeling to include NSBP. In October 2022, we received FDA approval of our latest generation SCS system, HFX iQ™, which we launched on a limited basis in the United States in the fourth quarter of 2022 and more fully in 2023. In September 2024, we announced the FDA approval and limited market release of HFX iQ™ with HFX AdaptivAI™, a responsive, personalized pain management platform powering the HFX iQ SCS system as our latest addition to the Senza family of products. We are continuing to invest in product improvements to Senza, including enhanced MRI capabilities and next generation IPGs. While R&D and clinical testing are time consuming and costly, we believe expanding into new indications, implementing product improvements and continuing to demonstrate the efficacy, safety and cost effectiveness of the 10 kHz Therapy through clinical data are all critical to increasing the adoption of this therapy.

The SENZA-PDN study was one of the largest RCT conducted in the field of spinal cord stimulation with 216 randomized patients. The study evaluated paresthesia-free 10 kHz Therapy among patients diagnosed with PDN and refractory to CMM. Patients were randomized one-to-one to CMM alone or CMM with 10 kHz Therapy. A crossover study design was used, where subjects who did not have adequate pain relief at 6 months were given the option to cross over to the other treatment arm. Subjects were followed for 24 months, with subjects who crossed over from CMM alone to CMM with 10 kHz Therapy followed for 24 months post-implantation. In April 2021, the six-month data were published online in *JAMA Neurology*. In July 2021, the FDA approved the Senza System for the treatment of chronic intractable pain of the lower limbs, including unilateral and bilateral pain, associated with PDN. This approval is specific to Nevro's unique 10 kHz SCS stimulation, and the Senza system was the first spinal cord stimulation system approved by the FDA with a specific indication to treat PDN. In September 2022, the study was completed, and the study results have been presented at numerous conferences and published in multiple journal publications.

Our other large RCT, the SENZA-NSRBP study, was executed to support the new indication for treatment of non-surgical back pain (NSBP) which includes patients with NSBP. NSBP is defined as chronic back pain in patients who have not had previous spine surgery, and based on an assessment from a spine surgeon, are not surgical candidates. The study compared patients receiving 10 kHz Therapy plus CMM to patients receiving CMM alone. In January 2022, the FDA approved the Senza System as an aid in the management of NSBP (intractable back pain without prior surgery and not a candidate for back surgery) based on 6 month efficacy data showing profound improvements in pain and function with 10 kHz Therapy over CMM alone. At the 2022 NANS conference, we presented our 12-month results, including six-month crossover patient data, for the SENZA-NSRBP study. Key findings at 12 months showed profound improvements in pain relief, function, quality of life measures, awareness of positive change and reduction in daily opioid use in NSBP patients receiving 10 kHz Therapy at 12-months post-implant. Results also included comparable improvements for patients that crossed over from CMM to 10 kHz after 6 months. In February 2022, the SENZA-NSRBP 12-month results were published online in the *Journal of Neurosurgery: Spine*. Finally, in January 2023, we presented the full 24-month results from the SENZA-NSRBP study at the 2023 NANS conference, and the full manuscript reporting the 24-month results was published in *Journal of Neurosurgery: Spine* in November 2023. We have utilized this 24-month publication in our Patient Access efforts by successfully obtaining case-by-case prior authorization approvals in the absence of defined payor medical policies or explicit non-coverage policies. We expect that this 24-month publication will be critical in efforts to expand payor coverage for this patient cohort.

### **Significant Investment in U.S. Sales Organization**

In 2021, we established a sales organization to support the launch of our PDN indication in the United States. This sales organization targets physician specialties involved in PDN treatment decisions, including primary care physicians, endocrinologists, internal medicine and podiatrists, to create awareness of 10 kHz Therapy to treat PDN patients. We are continuing to make investments in building our U.S. commercial infrastructure and recruiting and training our U.S. sales force. This is a lengthy process that requires recruiting appropriate sales representatives, establishing and, on occasion, refining a commercial infrastructure in the United States and training our sales representatives. Following initial training for Senza, our sales representatives typically require lead time in the field to grow their network of accounts and produce sales results. Successfully recruiting and training a sufficient number of productive sales representatives has been required to achieve growth at the rate we expect.

### **Access to Hospital Facilities**

In the United States, in order for physicians to use our products, the hospital facilities where these physicians treat patients often require us to enter into purchasing contracts directly with the hospital facilities or with the Group Purchasing Organizations of which the hospital facilities are members. This process can be lengthy and time-consuming and requires extensive negotiations and management time. In Europe, we may be required to engage in a contract bidding process in order to sell our products, where the bidding processes are only open at certain periods of time, and we may not be successful in the bidding process.

### **Critical Accounting Policies, Significant Judgments and Use of Estimates**

Our management's discussion and analysis of financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our significant accounting policies are more fully described in Note 1, *Summary of Significant Accounting Policies*, of Notes to Condensed Consolidated Financial Statements. There have been no significant or material changes in our critical accounting policies during the nine months ended September 30, 2024 to the items we disclosed as our critical accounting policies in Management's Discussion and Analysis of Financial Conditions and Results of Operations in our Annual Report.

### **Goodwill**

We assess goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amounts may not be recoverable. We have one reporting unit. Accordingly, our review of goodwill impairment indicators is performed at the entity-wide level. Goodwill is \$38.2 million as of September 30, 2024. We considered whether the decline in the price of our common stock, which resulted in our market capitalization dropping below the value of our net assets in the third quarter, would require us to perform an impairment assessment. We considered other factors including macroeconomic conditions, industry and market environments and other relevant company-specific events and concluded that it was not more likely than not that the fair value of our reporting unit is less than its carrying amount. Thus, an interim goodwill impairment assessment was not performed as of September 30, 2024. Further events and circumstances such as a continued or sustained decline in the price of our common stock, market capitalization or revenue could result in impairment of goodwill or long-lived assets.

### **Components of Results of Operations**

#### **Revenue**

Our revenue is generated primarily from sales to two types of customers: hospitals and outpatient medical facilities, with each being served primarily through a direct sales force. Sales to these entities are billed to, and paid by, the hospitals and outpatient medical facilities as part of their normal payment processes, with payment received by us in the form of an electronic transfer, check or credit card payment. Product sales to third-party distributors are billed to and paid by the distributors as part of their normal payment processes, with payment received by us in the form of an electronic transfer.

U.S. revenue is generally recognized after our sales representatives deliver our product at the point of implantation and upon the completion and authorization of the implant procedure. In response to competitive practices and pressures, we have offered some volume price discounting for larger orders, where products are ordered in advance of an implantation and revenue is recognized when the transfer of control occurs at the time of shipment.

Revenue from sales fluctuates based on the selling price of the products, as the average sales price of our products vary geographically and by the generation of the product sold, and based on the mix of sales by geography. Our revenue from international sales can also be significantly impacted by fluctuations in foreign currency exchange rates, as our sales are denominated in the local currency in the countries in which we sell our products.

We expect our revenue to fluctuate from quarter to quarter due to a variety of factors, including seasonality. For example, the industry generally experiences lower revenues in the first and third quarters of the year and higher revenues in the fourth quarter. Our revenue has been impacted by these industry trends. Further, the impact of the buying patterns and implant volumes of hospitals and medical facilities, and third-party distributors may vary, and as a result could have an effect on our revenue from quarter to quarter.

#### **Cost of Revenue**

Cost of revenue consists primarily of acquisition costs of components of our products, manufacturing overhead, scrap and inventory excess and obsolescence charges, as well as distribution-related expenses, such as logistics and shipping costs, net of costs charged to customers.

We calculate gross margin as revenue less cost of revenue divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, but primarily by our average sales price and the costs to have our products manufactured. While costs are primarily incurred in U.S. dollars, international revenue may be impacted by the appreciation or depreciation of the U.S. dollar, which may impact our overall gross margin. Our gross margin is also affected by our ability to reduce manufacturing costs as a percentage of revenue.

#### **Operating Expenses**

Our operating expenses consist of R&D expense and sales, general and administrative (SG&A) expenses, amortization of intangibles and change in fair value of contingent consideration. Personnel costs are the most significant component of operating expenses and consist primarily of salaries, bonus incentives, benefits, stock-based compensation and sales commissions.

**Research and Development.** R&D costs are expensed as incurred. R&D expense consists primarily of personnel costs, including salary, employee benefits and stock-based compensation expenses for our R&D employees. R&D expense also includes costs associated with product design efforts, development prototypes, testing, clinical trial programs and regulatory activities, contractors and consultants, equipment and software to support our development, facilities and information technology. We expect product development expenses to increase in absolute dollars as we continue to develop product enhancements to our products. Our R&D expenses may fluctuate from period to period due to the timing and extent of our R&D and clinical trial expenses.

**Sales, General and Administrative.** SG&A expense consists primarily of personnel costs, including salary, employee benefits and stock-based compensation expenses for our sales and marketing personnel, including sales commissions, and for administrative personnel that support our general operations, such as information technology, executive management, financial accounting, customer service and human resources personnel. We expense commissions at the time of the sale. SG&A expense also includes costs attributable to marketing, as well as travel, intellectual property and other legal fees, financial audit fees, insurance, fees for other consulting services, depreciation and facilities.

In 2021, we established a sales organization to support the launch of our PDN indication in the U.S. This sales organization targets physician specialties involved in PDN treatment decisions, including primary care physicians, endocrinologists, internal medicine and podiatrists, to create awareness of 10 kHz Therapy to treat PDN patients. We have continued to invest significant spend in marketing efforts in order to generate additional sales opportunities. Additionally, we have made substantial investments in our U.S. commercial infrastructure to support our commercialization efforts in the United States. We expect SG&A expenses to decrease as a percent of revenue as we engage in activities that leverage our existing sales and marketing personnel to support the commercialization of our products in the United States.

In the years leading up to 2022, we had experienced significant legal expenses associated with our intellectual property litigation with Boston Scientific. We continued to incur significant legal expenses associated with intellectual property litigation in 2023. Additionally, we continue to incur significant expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, including compliance under the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), director and officer insurance premiums and investor relations costs associated with being a public company. Our SG&A expense may fluctuate from period to period due to the seasonality of our revenue and the timing and extent of our SG&A expense.

**Amortization of Intangibles.** Our amortization expense relates to intangible assets acquired in a business combination or asset acquisition.

**Change in Fair Value of Contingent Consideration.** Our acquisition of Vyrsa includes a contingent consideration arrangement, for which we recognized a liability equal to the fair value of the contingent payments we expect to make. We re-measure this liability each reporting period and record any changes in fair value. Changes in discount rates, periods, timing and amount of projected revenue or timing or likelihood of achieving milestones may result in changes in the fair value.

#### **Interest Income and Interest Expense**

Interest income consists primarily of interest income earned on our investments and interest expense consists of interest paid on our outstanding debt and the amortization of debt discount and debt issuance costs.

#### **Change in Fair Value of Warrants**

The value of the Braidwell Warrants are remeasured to the Fair Market Value at the end of each reporting period while they remain outstanding. The change in the fair value of these warrants are recorded as change in fair value of warrants in our condensed consolidated statements of operations.

#### **Other Income (Expense), Net**

Other income (expense), net consists primarily of foreign currency transaction gains and losses and the gains and losses from the remeasurement of foreign-denominated balances to the U.S. dollar.

#### **Provision for Income Taxes**

The provision for income taxes consists primarily of income taxes in foreign jurisdictions in which we conduct business as well as states where we have determined we have state nexus. We maintain a full valuation allowance for all of our U.S. deferred tax assets including net operating loss (NOL) carryforwards and federal and state tax credits.

### **Consolidated Results of Operations**

#### **Comparison of the three months ended September 30, 2024 and 2023**

##### **Revenue, Cost of Revenue, Gross Profit and Gross Margin**

	Three Months Ended September 30,		
	2024	2023	Change
<b>(in thousands)</b>			
Revenue	\$ 96,910	\$ 103,862	\$ (6,952)
Cost of revenue	32,296	34,346	(2,050)
<b>Gross profit</b>	<b>\$ 64,614</b>	<b>\$ 69,516</b>	<b>\$ (4,902)</b>
Gross margin	67%	67%	0%

**Revenue.** Revenue decreased to \$96.9 million in the three months ended September 30, 2024 from \$103.9 million in the three months ended September 30, 2023, a decrease of \$7.0 million, or 7%. Revenue in the United States was \$83.9 million in the three months ended September 30, 2024, a 7% decrease from \$89.8 million in the three months ended September 30, 2023. International revenue was \$13.0 million in the three months ended September 30, 2024, compared to \$14.1 million in the three months ended September 30, 2023. Revenue decreased primarily due to a decrease in our trial and permanent implant volumes from the prior year.

**Cost of Revenue, Gross Profit and Gross Margin.** Cost of revenue decreased to \$32.3 million in the three months ended September 30, 2024 from \$34.3 million in the three months ended September 30, 2023, an decrease of \$2.1 million, or 6%. This was primarily driven by a decrease of \$3.1 million due to a decrease in the number of units sold and lower product costs as a result of moving production to our Costa Rica manufacturing facility, which was partially offset by an increase of \$0.8 million in the write-down of inventory. Gross profit decreased to \$64.6 million in the three months ended September 30, 2024 from \$69.5 million in the three months ended September 30, 2023, a decrease of \$4.9 million. Gross profit as a percentage of revenue, or gross margin, was 67% in each of the three months ended September 30, 2024 and 2023.

## Operating Expenses

(in thousands)	Three Months Ended September 30,		2024		2023		Change Amount
	Amount	% of Total Revenue	Amount	% of Total Revenue			
	Amount	% of Total Revenue	Amount	% of Total Revenue			
Operating expenses:							
Research and development	\$ 10,579	11%	\$ 13,923	13%	\$ (3,344)		
Sales, general and administrative	68,471	71%	81,152	78%	(12,681)		
Amortization of intangibles	737	1%	—	0%	737		
Change in fair value of contingent consideration	(1,307)	(1)%	—	0%	(1,307)		
Total operating expenses	<u>\$ 78,480</u>	<u>81%</u>	<u>\$ 95,075</u>	<u>92%</u>	<u>\$ (16,595)</u>		

*Research and Development Expense.* R&D decreased to \$10.6 million in the three months ended September 30, 2024, from \$13.9 million in the three months ended September 30, 2023, a decrease of \$3.3 million, or 24%. The decrease was primarily due to \$2.5 million decrease in personnel expenses due to the restructurings during the year, a decrease of \$0.3 million in development expenses and a decrease of \$0.3 million in office expenses.

*Sales, General and Administrative Expense.* SG&A expenses decreased to \$68.5 million in the three months ended September 30, 2024, from \$81.2 million in the three months ended September 30, 2023, a decrease of \$12.7 million, or 16%. The decrease was primarily due to decreases in legal expenses of \$4.5 million, marketing expenses of \$1.1 million, personnel expenses of \$5.6 million, consulting and outside services of \$1.0 million.

*Amortization of Intangibles.* Our amortization expense relates to intangible assets acquired in a business combination or asset acquisition. In the fourth quarter of 2023, we acquired Interventional Pain Technologies, Inc. (Vyrsa), which included \$27.6 million of intangible assets. We recorded amortization of \$0.7 million in the three months ended September 30, 2024 related to these intangibles.

*Change in Fair Value of Contingent Consideration.* To recognize changes in the fair value of our contingent consideration liability, we recorded a gain of \$1.3 million in the three months ended September 30, 2024.

## Interest Income, Interest Expense and Other Income (Expense), Net, and Provision for Income Taxes

(in thousands)	Three Months Ended September 30,		2024		2023		Change
	Amount	% of Total Revenue	Amount	% of Total Revenue	Amount	% of Total Revenue	
Interest income	\$ 3,226	\$ 3,594	\$ (368)				
Interest expense	(7,008)	(1,618)	(5,390)				
Change in fair market value of warrants	3,438	—	3,438				
Other income (expense), net	(854)	234	(1,088)				
Provision for income taxes	280	130	150				

*Interest Income.* Interest income decreased to \$3.2 million in the three months ended September 30, 2024 from \$3.6 million in three months ended September 30, 2023.

*Interest Expense.* Interest expense increased to \$7.0 million in the three months ended September 30, 2024 from \$1.6 million in the three months ended September 30, 2023. In November 2023, we entered into the Braidwell Credit Agreement, from which we recorded \$5.7 million in interest expense and \$1.0 million in the amortization of debt issuance costs in the three months ended September 30, 2024. The increase of interest expense from the Braidwell Credit Agreement was partially offset by a decrease of \$1.3 million in interest expense and amortization of debt issuance costs for the 2025 Notes, due to our repurchase of \$151.7 million in principal of our 2025 Notes in December 2023.

*Change in Fair Value of Warrants.* The value of the outstanding Braidwell Warrants requires remeasurement at each reporting date. The change in the fair value of these warrants was a gain of \$3.4 million in the three months ended September 30, 2024.

*Other Income (Expense), Net.* Other income (expense), net was primarily comprised of foreign currency transaction gains and losses, as well as gains and losses from the remeasurement of foreign-currency denominated balances.

**Provision for Income Taxes.** Income tax expense was \$0.3 million in the three months ended September 30, 2024 and \$0.1 million in the three months ended September 30, 2023. The income tax expense for both periods was principally comprised of foreign income tax and state income tax. We continued to have NOL carryforwards creating a deferred tax asset. We have a full valuation allowance for all of our U.S. deferred tax assets.

**Comparison of the nine months ended September 30, 2024 and 2023**

**Revenue, Cost of Revenue, Gross Profit and Gross Margin**

(in thousands)	Nine Months Ended September 30,		Change
	2024	2023	
Revenue	\$ 302,970	\$ 308,998	\$ (6,028)
Cost of revenue	99,361	100,415	(1,054)
Gross profit	<u>\$ 203,609</u>	<u>\$ 208,583</u>	<u>\$ (4,974)</u>
Gross margin	67%	68%	(1)%

**Revenue.** Revenue decreased to \$303.0 million in the nine months ended September 30, 2024 from \$309.0 million in the nine months ended September 30, 2023, a decrease of \$6.0 million, or 2.0%. Revenue in the United States was \$261.6 million in the nine months ended September 30, 2024, a 1% decrease from \$265.0 million in the nine months ended September 30, 2023. International revenue was \$41.4 million in the nine months ended September 30, 2024, compared to \$44.0 million in the nine months ended September 30, 2023. Revenue decreased primarily due to a decrease in our trial and permanent implant volumes from the prior year.

**Cost of Revenue, Gross Profit and Gross Margin.** Cost of revenue decreased to \$99.4 million in the nine months ended September 30, 2024 from \$100.4 million in the nine months ended September 30, 2023, a decrease of \$1.1 million, or 1%. This was primarily driven by a decrease of \$9.3 million due to a decrease in the number of units sold and lower product costs as a result of moving production to our Costa Rica manufacturing facility, which were partially offset by a \$6.0 million one-time supplier renegotiation charge, \$1.1 million increase in consumables and \$0.7 million increase in absorption costs. Gross profit decreased to \$203.6 million in the nine months ended September 30, 2024 from \$208.6 million in the nine months ended September 30, 2023, a decrease of \$5.0 million. Gross profit as a percentage of revenue, or gross margin, was 67% for the nine months ended September 30, 2024 compared to 68% for the nine months ended September 30, 2023.

**Operating Expenses**

(in thousands)	Nine Months Ended September 30,		Change		
	2024	2023			
	Amount	% of Total Revenue	Amount	% of Total Revenue	Change Amount
Operating expenses:					
Research and development	\$ 39,524	13%	\$ 41,998	14%	\$ (2,474)
Sales, general and administrative	233,571	77%	254,106	82%	(20,535)
Amortization of intangibles	2,211	1%	—	0%	2,211
Change in fair value of contingent consideration	3,124	1%	—	0%	3,124
Total operating expenses	<u>\$ 278,430</u>	<u>92%</u>	<u>\$ 296,104</u>	<u>96%</u>	<u>\$ (17,674)</u>

**Research and Development Expense.** R&D expenses decreased to \$39.5 million in the nine months ended September 30, 2024, from \$42.0 million in the nine months ended September 30, 2023, a decrease of \$2.5 million, or 6%. The decrease was primarily due to a decrease in personnel expenses of \$1.5 million and a decrease in development expenses of \$0.7 million.

**Sales, General and Administrative Expense.** SG&A expenses decreased to \$233.6 million in the nine months ended September 30, 2024, from \$254.1 million in the nine months ended September 30, 2023, a decrease of \$20.5 million, or 8%. The decrease was primarily due to decreases in legal expenses of \$11.6 million, decreases in personnel expenses of \$4.7 million, marketing expenses of \$4.0 million and conference expenses of \$1.6 million, partially offset by increases in employee and physician training expenses of \$2.0 million.

**Amortization of Intangibles.** Our amortization expense relates to intangible assets acquired in a business combination or asset acquisition. In the fourth quarter of 2023, we acquired Vyrsa, which included \$27.6 million of intangible assets. We recorded amortization of \$2.2 million in the nine months ended September 30, 2024 related to these intangibles.

**Change in Fair Value of Contingent Consideration.** To recognize changes in the fair value of our contingent consideration liability, we recorded net expenses of \$3.1 million in the nine months ended September 30, 2024.

#### Interest Income, Interest Expense and Other Income (Expense), Net, and Provision for Income Taxes

(in thousands)	Nine Months Ended September 30,		Change
	2024	2023	
Interest income	\$ 10,323	\$ 10,220	\$ 103
Interest expense	(20,261)	(4,849)	(15,412)
Change in fair market value of warrants	26,502	—	26,502
Other income (expense), net	(1,147)	(150)	(997)
Provision for income taxes	924	932	(8)

**Interest Income.** Interest income increased slightly to \$10.3 million in the nine months ended September 30, 2024 from \$10.2 million in the nine months ended September 30, 2023, primarily due to a higher average investment return rates during 2024.

**Interest Expense.** Interest expense increased to \$20.3 million in the nine months ended September 30, 2024 from \$4.8 million in the nine months ended September 30, 2023. In November 2023, we entered into the Braidwell Credit Agreement, from which we recorded \$16.6 million in interest expense and \$2.7 million in the amortization of debt issuance costs in the nine months ended September 30, 2024. The increase of interest expense from the Braidwell Credit Agreement was offset by a decrease of \$3.9 million in interest expense and amortization of debt issuance costs for the 2025 Notes, due to our repurchase of \$151.7 million in principal of our 2025 Notes.

**Change in Fair Value of Warrants.** The value of the outstanding Braidwell Warrants requires remeasurement at each reporting date. The change in the fair value of these warrants was a gain of \$26.5 million in the nine months ended September 30, 2024.

**Other Income (Expense), Net.** Other income (expense), net was primarily comprised of foreign currency transaction gains and losses, as well as gains and losses from the remeasurement of foreign-currency denominated balances.

**Provision for Income Taxes.** Income tax expense was \$0.9 million in each of the nine months ended September 30, 2024 and 2023. The income tax expense for both periods was principally comprised of foreign income tax and state income tax. We continued to have NOL carryforwards creating a deferred tax asset. We have a full valuation allowance for all of our U.S. deferred tax assets.

#### Liquidity, Capital Resources and Plan of Operations

Since our inception, we have financed our operations through revenue generated from our operations, private placements of preferred stock, the issuance of common stock in our IPO in November 2014 and our underwritten public offering in June 2015, borrowings under our credit facility, which we have subsequently repaid, and the June 2016 issuance of convertible senior notes due 2021 (2021 Notes). In April 2020, we completed a concurrent underwritten public offering of common stock and convertible senior notes due 2025. Our total net proceeds from the April 2020 offerings, after giving effect to the note hedge transactions and warrant transactions and associated offering expense, was \$313.3 million. On June 1, 2021, our outstanding 2021 Notes matured and we paid \$172.5 million to settle the outstanding principal and issued 682,912 shares of common stock to holders who elected to convert the 2021 Notes. In November 2023, we entered into the Braidwell Credit Agreement for \$200.0 million, and we used portions of the proceeds to repurchase \$151.7 million of our 2025 Notes. As of September 30, 2024, we had cash, cash equivalents and short-term investments of \$277.0 million. Based on our current operating plan, we expect that our cash and cash equivalents and short-term investments, together with the anticipated funds from the collection of our receivables, will be sufficient to fund our operations through at least the next 12 months.

We expect to incur continued expenditures in the future in support of our commercial infrastructure and sales force. In addition, we intend to continue to make investments in the further development of our products, including ongoing R&D programs and conducting clinical trials. In order to further enhance our R&D efforts, pursue product expansion opportunities or acquire a new business or products that are complementary to our business, we may choose to raise additional funds.

We may continue to seek funds through equity or debt financings, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. Should we choose to raise additional capital, the requirements will depend on many factors, including:

- the impact from any recession or other adverse macroeconomic conditions, including but not limited to increased interest rates, inflationary pressures, geopolitical conflicts and lower consumer confidence;
- the costs related to the continued commercialization of our products in the United States and elsewhere, including product sales, marketing, manufacturing and distribution;
- the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
- the R&D activities we intend to undertake in order to expand the chronic pain indications and product enhancements that we intend to pursue;
- whether or not we pursue acquisitions or investments in businesses, products or technologies that are complementary to our current business;
- the degree and rate of market acceptance of our products in the United States and elsewhere;
- changes or fluctuations in our inventory supply needs and forecasts of our supply needs;
- costs related to the development of our internal manufacturing capabilities;
- our need to implement additional infrastructure and internal systems;
- our ability to hire additional personnel to support our operations as a public company; and
- the emergence of competing technologies or other adverse market developments.

Our success depends, in part, upon our ability to establish a competitive position in the neuromodulation market by securing broad market acceptance of our 10 kHz Therapy and our Senza product platform for the treatment of chronic pain conditions, as well as our ability to gain market acceptance for other products, such as our SI Joint product portfolio. Any product we develop that achieves regulatory clearance or approval will have to compete for market acceptance and market share. We face significant competition in the United States and internationally, which we believe will intensify as we continue to commercialize in the United States. For example, our major competitors, Medtronic, Boston Scientific and Abbott Laboratories, each have approved neuromodulation systems in at least the United States, Europe and Australia and have been established for several years. In addition to these major competitors, we may also face competition from other emerging competitors and smaller companies with active neuromodulation system development programs that may emerge in the future.

If we are unable to raise, or have access, to sufficient funds when needed, we may be required to delay, reduce, or terminate some or all of our commercial development plans.

The following table sets forth the primary sources and uses of cash for each of the periods presented below:

	Nine Months Ended September 30, 2024		2023	
(in thousands)				
Net cash provided by (used in)				
Operating activities	\$	(38,034)	\$	(49,906)
Investing activities		9,359		(6,091)
Financing activities		(4,837)		836
Effect of exchange rate on cash flows		1,277		(57)
Net decrease in cash, cash equivalents and restricted cash	\$	<u>(32,235)</u>	\$	<u>(55,218)</u>

**Cash Provided by (Used in) Operating Activities.** Net cash used in operating activities was \$38.0 million in the nine months ended September 30, 2024, compared to \$49.9 million in the nine months ended September 30, 2023. In the nine months ended September 30, 2024, net cash used in operating activities was primarily a result of the net loss recorded during the period of \$60.3 million. The cash used in operating activities for the nine months ended September 30, 2024 was affected by a decrease in accounts payable and accrued liabilities of \$15.9 million and change in fair value of warrants of \$26.5 million. These changes were partially offset by the recording of non-cash stock-based compensation expense of \$38.7 million, non-cash interest expense of \$8.2 million, depreciation and amortization of \$6.0 million, change in fair value of contingent consideration of \$3.1 million and a decrease in accounts receivable of \$7.5 million. In the nine months ended September 30, 2023, net cash used in operating activities was primarily

a result of the net loss recorded during the period of \$83.2 million and amortization of premiums in our debt securities of \$2.8 million, as well as increases in inventory of \$24.8 million and decreases in other long term liabilities of \$4.1 million. These changes were partially offset by the recording of non-cash stock-based compensation expense of \$43.2 million, depreciation and amortization of \$4.9 million, amortization of operating lease assets of \$3.3 million and write-down of inventory of \$3.0 million, as well as decreases in accounts receivable of \$9.4 million.

*Cash Provided by (Used in) Investing Activities.* Investing activities consisted primarily of changes in investment balances, including purchases and maturities of short-term investments. We had net proceeds from the maturity of short-term investments of \$17.2 million in the nine months ended September 30, 2024 and \$2.5 million in the nine months ended September 30, 2023. We also had purchases of property and equipment of \$7.8 million and \$6.7 million in the nine months ended September 30, 2024 and 2023, respectively. Additionally, we purchased secured convertible notes issued by a private company totaling \$1.9 million in the nine months ended September 30, 2023.

*Cash Provided by (Used in) Financing Activities.* Financing activities consisted primarily of tax withholdings for net share settlement and cash received from the issuance of common stock to employees pursuant to the exercise of employee stock options and our employee stock purchase plan. In the nine months ended September 30, 2024, we had proceeds from issuance of common stock of \$2.7 million, offset by tax withholdings of \$2.3 million. Additionally, during the nine months ended September 30, 2024, we made a \$5.0 million payment related to the contingent consideration. In the nine months ended September 30, 2023, we had proceeds from issuance of common stock of \$5.2 million, offset by tax withholdings of \$4.4 million.

#### **Restructuring**

On January 6, 2024, we approved a restructuring plan to accelerate our path to profitability that included laying off 63 employees, which represented approximately 5% of our total number of employees. Operating expenses for the three months ended March 31, 2024 reflected a \$5.5 million restructuring charge, consisting of one-time severance and other termination benefit costs. During the three months ended June 30, 2024 and September 30, 2024, we approved additional restructuring steps to further accelerate its path to profitability. Operating expenses for the three months ended June 30, 2024 and September 30, 2024 reflected a restructuring charge of \$4.6 million and \$0.7 million, respectively, consisting of one-time severance and other termination benefit costs. For the nine months ended, September 30, 2024, we recognized \$10.8 million of restructuring charge. As of September 30, 2024, substantially all severance and other termination benefit amounts have been paid.

#### **Contractual Obligations and Commitments**

We have lease obligations primarily consisting of operating leases for our principal offices, which expire as set forth below, and for our warehouse space. In 2020, we also entered into an operating lease for a manufacturing facility with an expiration date of June 2031.

In March 2015, we entered into a lease agreement for approximately 50,740 square feet of office space located in Redwood City, California for a period beginning in June 2015 and ending in May 2022, with initial annual payments of approximately \$2.0 million, increasing to \$2.4 million annually in the final year of the lease term. In December 2016, we entered into a first amendment to the lease for an additional approximately 49,980 square feet of office space adjacent to the premises under the original lease (the Expansion Premises) with initial annual payments of \$1.2 million, increasing to \$2.9 million in the final year of the amended lease term. The lease for the Expansion Premises commenced on June 1, 2018. The first amendment also extends the lease term for the original premises to terminate on the same date as the amended lease, which is May 31, 2025. In April 2024, we entered into an amendment which reduced the total office space to approximately 77,620 square feet, beginning June 1, 2024 through December 31, 2031, with annual payments of \$3.0 million, increasing to \$5.7 million in the final year of the amended lease term. See Note 6, *Commitments and Contingencies*, of Notes to Condensed Consolidated Financial Statements for additional information.

In February 2017, we entered into a separate non-cancellable facility lease for warehouse space beginning March 1, 2017 through February 28, 2022, under which we are obligated to pay approximately \$0.4 million in lease payments over the term of the lease. In October 2021, we extended our warehouse lease through May 2025, under which we are obligated to pay approximately \$0.4 million over the extended term.

In August 2020, we entered into a lease for approximately 35,411 square feet of manufacturing space to begin in April 2021 and to last through June 2031 at a facility in Costa Rica, under which we are obligated to pay approximately \$3.9 million in lease payments over the term of the lease. We currently use this facility to build-out certain manufacturing capabilities so that we can vertically integrate the assembly of IPGs, peripherals and various other manufacturing related activities.

In September 2024, we entered into a lease for 13,623 square feet of warehouse space located in Plymouth Meeting, Pennsylvania to commence on the later of December 1, 2024 or completion of the landlord's building improvements. The lease is through February 2033, under which we are obligated to pay \$2.0 million over the term of the lease.

We have entered into supply agreements with certain suppliers that require certain minimum annual purchase agreements. As of September 30, 2024, we had minimum annual purchase commitments of \$1.1 million due for the remainder of 2024 and \$4.9 million due in 2025. In addition, we renegotiated a supplier contract resulting in a one-time \$6.0 million fee, expensed as of June 30, 2024. We paid \$4.0 million of the renegotiation fee during the three months ended September 30, 2024. The renegotiation reduced our future purchase commitments enabling us to accelerate the move of inventory production to our Costa Rica facility.

As of September 30, 2024, our contractual obligations related to the 2025 Notes are payments of interest of \$0.5 million due for the remainder of 2024 and payments of interest and principal totaling \$38.6 million due in April 2025.

As of September 30, 2024, our contractual obligations related to the Braidwell Term Loan are payments of interest of \$2.8 million due for the remainder of 2024, \$17.3 million due in 2025, \$17.9 million due in 2026 and \$20.3 million due in 2027, as well as payments of interest, principal and fees totaling \$46.1 million due in 2028 and \$232.1 million in 2029.

#### **Off-Balance Sheet Arrangements**

Through September 30, 2024, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. For information regarding indemnification obligations, refer to Note 6, *Commitments and Contingencies*, of Notes to Condensed Consolidated Financial Statements within this report.

#### **Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Our exposures to other market risks related to fluctuation in interest rates, market prices, and foreign currency exchange have not changed materially since December 31, 2023. For quantitative and qualitative disclosures about market risk, see Item 7A, *Quantitative and Qualitative Disclosures About Market Risk*, in our Annual Report.

#### **Item 4. Controls and Procedures**

##### **Evaluation of Disclosure Controls and Procedures**

The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024, the end of the period covered by this Quarterly Report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

##### **Changes in Internal Control over Financial Reporting**

There was no change in our internal control over financial reporting that occurred during the three months ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## PART II: OTHER INFORMATION

### Item 1. Legal Proceedings

The legal proceedings information set forth in Note 6, *Commitments and Contingencies*, of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Quarterly Report is incorporated herein by reference.

### Item 1A. Risk Factors

In addition to other information contained elsewhere in this Quarterly Report, you should carefully consider the risk factors discussed in Part I, Item 1A, *Risk Factors* in our Annual Report as filed on February 23, 2024, which could materially affect our business, financial condition, or future results. There have been no material changes to our risk factors since our Annual Report, except as described below.

#### Risks Related to our Business

***Declines in our market capitalization could result in the recognition of an impairment charge to goodwill, net tangible assets or identifiable intangible assets, which could have an adverse impact on our results of operations and the market value of our common stock.***

We review our identifiable intangible assets and other long-lived assets for impairment annually or when events or changes in circumstances indicate the carrying value may not be recoverable. The total purchase price pertaining to our acquisitions have been allocated to goodwill, net tangible assets, and identifiable intangible assets. See Note 8, Goodwill and Intangible Assets, of Notes to Condensed Consolidated Financial Statements for additional information. An adverse change in market conditions, significant decrease in market capitalization, particularly if such change has the effect of changing one of our critical assumptions or estimates, could result in a change to the estimation of fair value that could result in an impairment charge to our goodwill, net tangible assets or identifiable intangible assets. To the extent the value of goodwill, net tangible assets or identifiable intangible assets become impaired, we may be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.

### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

#### Unregistered Sales of Equity Securities

None.

#### Use of Proceeds

None.

### Item 3. Defaults Upon Senior Securities.

None.

### Item 4. Mine Safety Disclosures.

Not applicable.

### Item 5. Other Information.

During the three months ended September 30, 2024, none of our officers or directors adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement".

**Item 6. Exhibits**

Exhibit Number	Description of Document	Form	Incorporated by Reference	Number	Filed Herewith
3.1	<a href="#">Amended and Restated Certificate of Incorporation.</a>	8-K	11/12/2014	3.1	
3.2	<a href="#">Certificate of Amendment of Amended and Restated Certificate of Incorporation.</a>	8-K	5/24/2019	3.1	
3.3	<a href="#">Amended and Restated Bylaws.</a>	8-K	11/12/2014	3.2	
3.4	<a href="#">Amendment to Amended and Restated Bylaws.</a>	8-K	5/24/2019	3.2	
4.1	<a href="#">Reference is made to Exhibits 3.1 to 3.3.</a>				
4.2	<a href="#">Form of Common Stock Certificate.</a>	S-1/A	10/27/2014	4.2	
4.3	<a href="#">Indenture, dated as of June 13, 2016, by and between the Company and Wilmington Trust, National Association.</a>	8-K	6/13/2016	4.1	
4.4	<a href="#">Second Supplemental Indenture, dated April 6, 2020, by and between Nevro Corp. and Wilmington Trust, National Association, as Trustee.</a>	8-K	4/7/2020	4.2	
4.5	<a href="#">Form of 2.75% Senior Convertible Note Due 2025 (included in Exhibit 4.5).</a>	8-K	4/7/2020	4.3	
4.6	<a href="#">Description of Nevro Corp.'s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a>	10-K	2/25/2020	4.6	
4.7	<a href="#">Form of Warrant to Purchase Common Stock of Nevro Corp.</a>	8-K	12/1/2023	4.1	
31.1	<a href="#">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a>				X
31.2	<a href="#">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).</a>				X
32.1**	<a href="#">Certification required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the</a>				X

Exhibit Number	Description of Document	Incorporated by Reference			Filed Herewith
		Form	Date	Number	
	United States Code (18 U.S.C. §1350).				
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.				X
101.SCH	Inline XBRL Taxonomy Extension Schema Document				X
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).				

# Indicates management contract or compensatory plan.

\*\* The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Nevro Corp. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**NEVRO CORP.**  
(Registrant)

Date: November 12, 2024

/s/ KEVIN THORNAL  
Kevin Thornal  
Chief Executive Officer  
(Principal Executive Officer)

Date: November 12, 2024

/s/ RODERICK H. MACLEOD  
Roderick H. MacLeod  
Chief Financial Officer  
(Principal Financial Officer)

**CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO  
SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Kevin Thornal, certify that:

- 1.I have reviewed this Quarterly Report on Form 10-Q of Nevro Corp.;
- 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2024

/s/ Kevin Thornal  
Kevin Thornal  
Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO  
SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Roderick H. MacLeod, certify that:

- 1.I have reviewed this Quarterly Report on Form 10-Q of Nevro Corp.;
- 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 12, 2024

/s/ RODERICK H. MACLEOD  
Roderick H. MacLeod  
Chief Financial Officer  
(Principal Financial Officer)

---

**CERTIFICATIONS PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Nevro Corp. (the "Company") on Form 10-Q for the fiscal quarter ended September 30, 2024, as filed with the Securities and Exchange Commission (the "Report"), Kevin Thornal, Chief Executive Officer of the Company, and Roderick H. MacLeod, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 12, 2024

/s/ KEVIN THORNAL  
Kevin Thornal  
Chief Executive Officer  
(Principal Executive Officer)

/s/ RODERICK H. MACLEOD  
Roderick H. MacLeod  
Chief Financial Officer  
(Principal Financial Officer)

---

